- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01066494
A Pharmacokinetic and Efficacy Study of Amonafide L-malate (AS1413) in Combination With Cytarabine in Patients With Acute Myeloid Leukemia (AML)
January 14, 2011 updated by: Antisoma Research
A Phase IIa Pharmacokinetic and Efficacy Study of Amonafide L-malate (AS1413) in Combination With Cytarabine in Adult Patients With Acute Myeloid Leukemia (AML)
A phase IIa study to evaluate the pharmacokinetic and efficacy of amonafide L-malate (AS1413) in combination with cytarabine in treating patients with acute myeloid leukemia (AML)
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
20
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tbilisi, Georgia, 0186
- Medulla - Chemotherapy and Immunotherapy Clinic
-
Tbilisi, Georgia, 0177
- Institute of Haematology and Transfusiology
-
Tbilisi, Georgia
- Hema - Haematology and Chemotherapy Clinic
-
-
-
-
-
Donetsk, Ukraine, 83045
- Institure of URgent adn Recovery Surgery n.a. V.K. gusaka of Academy Medical Science of Ukraine
-
Kiev, Ukraine, 03115
- Kyiv bone Marrow Transplantation Centre
-
Vinnytsya, Ukraine, 21018
- Vinnytsya Regional Clinical Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Willing and able to provide written informed consent
- In the opinion of the Investigator able to comply with the study assessments and follow-up
- New diagnosis of AML (i.e. >20 % blasts) as defined by the World Health Organization (WHO) classification (Vardiman 2009) or relapsed or refractory AML as defined by the persistence or recurrence of >5% blasts in bone marrow or peripheral blood following treatment.
- ECOG Performance status ≤ 2
- Age > 18 years and ≤ 70 years
Adequate hepatic function as evidenced by the following laboratory tests:
- Total serum bilirubin ≤ 1.5 x ULN or direct (conjugated) bilirubin ≤ 1.5 ULN unless attributable to suspected hepatic involvement with AML
- Serum AST and ALT ≤ 1.5 x ULN unless attributable to suspected hepatic involvement with AML
- Adequate renal function as evidenced by serum creatinine ≤ 1.5 x ULN
- Women of childbearing potential must have a negative serum pregnancy test. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant. This includes women who are using contraceptives or whose sexual partners are either sterile or using contraceptives
- Left Ventricular Ejection Fraction (LVEF) > 50%, as determined by multiplegated acquisition scan (MUGA) or echocardiogram (ECHO) within 28 days prior to administration of 1st dose of remission induction chemotherapy
Exclusion Criteria:
- Unwilling to accept the required per protocol blood and urine sample collection
- An initial diagnosis of acute promyelocytic leukemia as defined by French- American-British criteria (Bennett 1976) (otherwise known as FAB M3)
- Clinically active CNS leukemia
- History of clinically significant allergic reactions attributed to compounds of similar chemical or biological composition to amonafide or cytarabine
- Pregnant or breast feeding
- Known HIV positive
- Known active hepatitis B or C, or any other active liver disease
- Evidence of pulmonary infection. Patients with evidence of pulmonary infection on screening chest x-ray should have chest computed tomography (CT) prior to starting remission induction therapy to confirm absence or presence of pulmonary infection.
- Any major surgery or radiation therapy within 30 days prior to study entry
- Previously received treatment with amonafide
- Treatment with other investigational agents for any reason within 30 days prior to study entry
- Prior remission induction therapy for AML within 30 days of starting amonafide therapy
- Persistent non-hematologic toxicity (other than alopecia) greater than Grade 2 from prior therapy for MDS or AML
- Serious concomitant illnesses (for example, unstable angina or myocardial infarction or stroke within 3 months prior to study entry, congestive heart
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Single-arm
Amonafide 600 mg/m2 IV over 4 hours daily on days 1-5 in combination with cytarabine 200 mg/m2 IV continuous infusion (CI) daily on days 1-7
|
Amonafide 600 mg/m2 IV over 4 hours daily on days 1-5 in combination with cytarabine 200 mg/m2 IV continuous infusion (CI) daily on days 1-7
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To define the plasma PK Profile of amonafide and metabolite(s)
Time Frame: 1 year
|
1 year
|
To deine the urniary excretion of amonafide and metabolite(s)
Time Frame: 1 year
|
1 year
|
To investigate the fecal excretion of amonafide and metabolite(s) in selected patients
Time Frame: 1 year
|
1 year
|
To evaluate the safety and tolerability of amonafide in combination with cytarabine
Time Frame: 1 year
|
1 year
|
To evaluate the remission rate
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
All outcomes are of equal weighting
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2010
Primary Completion (ANTICIPATED)
September 1, 2010
Study Completion (ANTICIPATED)
January 1, 2011
Study Registration Dates
First Submitted
February 9, 2010
First Submitted That Met QC Criteria
February 9, 2010
First Posted (ESTIMATE)
February 10, 2010
Study Record Updates
Last Update Posted (ESTIMATE)
January 17, 2011
Last Update Submitted That Met QC Criteria
January 14, 2011
Last Verified
January 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Cytarabine
- Amonafide
Other Study ID Numbers
- AS1413-C-101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Jacqueline Garcia, MDEli Lilly and CompanyCompletedCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia | Refractory Adult Acute Myeloid LeukemiaUnited States
-
University of NebraskaNational Cancer Institute (NCI)Active, not recruitingSecondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Adult Acute Myeloid LeukemiaUnited States
Clinical Trials on Amonafide + cytarabine
-
Antisoma ResearchUnknownSecondary Acute Myeloid Leukemia (Secondary AML, sAML)Korea, Republic of, United States, Spain, United Kingdom, Australia, Austria, Taiwan, Israel, Italy, Belgium, Germany, France, Romania, Estonia, Canada, Ukraine, Ecuador, Hungary, Poland, Chile, Argentina, Czech Republic, Russian Federation
-
Xanthus Pharmaceuticals, Inc.CompletedAcute Myeloid LeukemiaUnited States, Canada
-
Xanthus Pharmaceuticals, Inc.Completed
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedBreast CancerUnited States
-
Sunesis PharmaceuticalsCompletedAcute Myeloid LeukemiaUnited States, Canada, Spain, Belgium, Korea, Republic of, Australia, France, Germany, Poland, New Zealand, United Kingdom, Czechia, Austria, Hungary, Italy
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Chronic Myelomonocytic Leukemia | Refractory Chronic Myelomonocytic Leukemia | Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome | Blasts 10-19 Percent of Bone Marrow Nucleated Cells and other conditionsUnited States
-
Jianxiang WangUnknownAcute Myeloid LeukemiaChina
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)RecruitingRefractory Acute Myeloid Leukemia | Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | Persistent DiseaseUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAcute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid LeukemiaUnited States
-
M.D. Anderson Cancer CenterRecruitingMyelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myeloproliferative Neoplasm | Acute Myeloid Leukemia With Gene MutationsUnited States